The National Institutes of Health Commercial Accelerator Program helps small healthcare and life science companies bring their products to market.
Using the publicly available ImmPort database, researchers standardized and analyzed immune-related data for more than 10,300 healthy individuals.
The company is marketing the panel, which runs on NanoString Technologies' nCounter System, to chemical and cosmetics firms as a replacement for animal models.
Data for hundreds of thousands of participants led to 20 new risk loci for allergic rhinitis, which were further examined by functional annotation and fine mapping.
The test is based on the company's GARD platform for measuring genetic biomarkers of immune reactions to predict chemical sensitivities.
The lab will launch a carrier screening test this year, and plans to bring infectious disease, allergy, cognitive health, and toxicology tests as well.
With RNA sequencing on blood samples taken before, during, and after peanut exposure, investigators searched for acute allergy-related genes and cell types.
This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.
The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.
Researchers find that people's genetics influence their success at university, but that it is not the only factor.
In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.